Reflection of modern concepts of therapy in the treatment of allergic diseases of the nose and paranasal sinuses

Abstract

The article highlights the urgent problem of modern medicine - allergic diseases. Over the past decades, there has been a significant increase in the prevalence of this pathology, the share of which in the general structure of the incidence of the population remains high to this day. The statistics are staggering. According to various sources, various manifestations of allergies affect from 10% to 40% of the world’s population. According to conservative estimates, more than 500 million people in the world. According to epidemiological studies, the amount of atopy is growing by 5-6% every year. The disease has a huge impact on the quality of life of the patient. Needless to say, an allergic disease can be accompanied by complications, including life-threatening. The big financial burden on the budget of our country is the economic costs of combating allergies and its complications. Therefore, the treatment of this nasology is one of the key issues both in the global and in Russian healthcare.Intranasal (topical) corticosteroids (IKS) are the drug of choice in the treatment of patients diagnosed with allergic rhinitis (AR). However, ICS are widely used in clinical practice and in the treatment of other diseases of the nose and paranasal sinuses. Depending on the nature of the pathological process, the duration of the drug can vary widely: from two weeks to several months or years. The purpose of this work is to systematize relevant publications and analyze possible uses for this group of drugs. The article reflects the issues of epidemiology, etiopathogenesis of allergic rhinitis. Consistently considered modern methods of treatment, in particular the use of (ICS) in therapy regimens. The results of international multicenter randomized controlled clinical trials are presented, the purpose of which was to determine and evaluate the efficacy and tolerability of ICS, in particular fluticasone propionate. It is concluded that fluticasone propionate is a modern and effective agent for the pathogenetic treatment of patients with not only allergic but also non-allergic rhinitis and can be recommended in the modern treatment regimen for both allergic and non-allergic rhinitis.